Hematological Oncology最新文献

{"title":"Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis","authors":"Lucio N. Gordan,&nbsp;Rohan Medhekar,&nbsp;Alex Z. Fu,&nbsp;Mostafa Shokoohi,&nbsp;Abril Oliva Ramirez,&nbsp;Nicolle Bonar,&nbsp;Bao-Ngoc Nguyen,&nbsp;Michaela Spence,&nbsp;Rebecca McTavish,&nbsp;Tim Disher,&nbsp;Santosh Gautam,&nbsp;Niodita Gupta-Werner,&nbsp;Shuchita Kaila,&nbsp;Anjan J. Patel","doi":"10.1002/hon.70061","DOIUrl":"https://doi.org/10.1002/hon.70061","url":null,"abstract":"<p>Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are guideline-recommended preferred regimens for initial treatment of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). This study aimed to systematically identify evidence on the clinical effectiveness of DRd and VRd as first-line treatments for patients with TIE NDMM and to conduct a meta-analysis. Ovid MEDLINE, Embase, and Cochrane Library were searched from January 2019 to June 2023, along with key congresses from January 2018 to June 2023. Bibliographies of relevant systematic literature reviews (SLR) were hand-searched. Randomized controlled trials and appropriately adjusted non-randomized studies comparing DRd versus VRd as first-line treatment for TIE NDMM were included. Overall, five records from three unique studies were identified. The fixed-effects meta-analysis showed a lower risk of disease progression or death with DRd versus VRd using the naïve approach (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.46, 0.77) as well as with the adjusted approach, which accounted for both double counting (i.e., two studies shared one comparison) and variance inflation due to studies with moderate and high risk of bias (HR: 0.56; 95% CI: 0.39, 0.82). In the absence of clinical trials with head-to-head comparison of these treatment regimens, these results could help inform the selection of optimal first-line treatment for TIE NDMM patients.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs","authors":"Chan Tze Wei,&nbsp;Hein Than,&nbsp;Feng-Ju Huang,&nbsp;Gauri Billa,&nbsp;Lai Heng Lee","doi":"10.1002/hon.70053","DOIUrl":"https://doi.org/10.1002/hon.70053","url":null,"abstract":"<p>Myelofibrosis (MF) is characterized by anemia, constitutional symptoms, hepatosplenomegaly and bone marrow fibrosis, and is associated with poor survival. The janus kinase inhibitor (JAKi) ruxolitinib has been the mainstay of treatment for over a decade. Despite demonstrated symptomatic and quality of life improvement, unmet clinical needs persist. A literature review identified promising novel targeted treatment options in MF using pre-set selection criteria (available Phase 2 or 3 data, minimum enrollment of 50 patients, trial end date within the last 5 years). Available data for novel and approved therapies were extracted, tabulated, and analyzed for clinical relevancy. From an initial shortlist of 48, 16 retained molecules were selected for inclusion. Other JAKi (pacritinib, momelotinib, jaktinib) address treatment-related cytopenia, expanding the therapeutic utility of this class of agents to patients with baseline anemia or thrombocytopenia. Novel candidates exploit multiple molecular pathways, and offer the potential to improve the management of MF-associated cytopenia (imetelstat, pelabresib, navitoclax, selinexor, luspatercept, sotatercept, elritercept, LCL161, bomedemstat) and recover bone marrow fibrosis (imetelstat, pelabresib, navitoclax and bomedemstat). It remains to be seen if these newer agents can induce any remission in MF and enable patients to come off therapy, but the future is beginning to look much brighter.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70053","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Hematological Malignancies Using N-NOSE (Nematode-NOSE)","authors":"Shingen Nakamura,&nbsp;Hideyuki Hatakeyama,&nbsp;Sumiko Yoshida,&nbsp;Umbhorn Ungkulpasvich,&nbsp;Takaaki Hirotsu,&nbsp;Eric di Luccio,&nbsp;Masahiro Abe","doi":"10.1002/hon.70062","DOIUrl":"https://doi.org/10.1002/hon.70062","url":null,"abstract":"<p>Hematological malignancies often lack defined risk factors and present with non-specific symptoms, underscoring the urgent need for simple and reliable detection methods. To address this challenge, Hirotsu et al. innovated N-NOSE, a novel, non-invasive cancer screening test that utilizes the chemotaxis response of the nematode <i>Caenorhabditis elegans</i> to detect tumor-related odors in urine. In this clinical study, we assessed the performance of N-NOSE in patients with various hematological malignancies at diagnosis and during treatment. Urine samples were collected from 30 healthy individuals and 89 patients, including those with leukemia (<i>n</i> = 13), malignant lymphoma (<i>n</i> = 53), multiple myeloma (<i>n</i> = 15), primary AL amyloidosis (<i>n</i> = 3), Waldenström's macroglobulinemia (<i>n</i> = 2), myelodysplastic syndrome (<i>n</i> = 2), and blastic plasmacytoid dendritic cell neoplasm (<i>n</i> = 1). Based on the optimal cut-off values in detecting hematological malignancies, N-NOSE demonstrated high positivity rates in treatment-naïve patients: leukemia and multiple myeloma were very high (over 90%), whereas malignant lymphoma was slightly lower than 80%. In the small subset of malignant lymphoma patients who tested N-NOSE-negative, confounding factors included steroid administration and hemodialysis. Importantly, no significant correlation emerged between N-NOSE index values and baseline characteristics or comorbidities other than the presence of cancer. Moreover, in all 32 patients who achieved clinical response following chemotherapy, the N-NOSE index declined, reflecting disease status. These findings highlight N-NOSE's strong potential as a sensitive, non-invasive screening tool for hematological malignancies—particularly multiple myeloma—and support its use in initial detection and monitoring of therapeutic response.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid and Sensitive Detection of the MYD88 L265P Mutation for Lymphoplasmocytic Lymphoma/Waldenström's Macroglobulinemia via CRISPR-Cas12a","authors":"Rumei Sun,&nbsp;Xiaping Miao,&nbsp;Qingyang Jiang,&nbsp;Xijie Fan,&nbsp;Yuxin Chen,&nbsp;Zhiying Mai,&nbsp;Kaimin Li,&nbsp;Tao Chen","doi":"10.1002/hon.70059","DOIUrl":"https://doi.org/10.1002/hon.70059","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis","authors":"Fenghua Gao,&nbsp;Cong Sun,&nbsp;Jing Liu,&nbsp;Jingwei Yu,&nbsp;Jin He,&nbsp;Xiangrui Meng,&nbsp;Xia Liu,&nbsp;Xue Han,&nbsp;Lanfang Li,&nbsp;Lihua Qiu,&nbsp;Zhengzi Qian,&nbsp;Shiyong Zhou,&nbsp;Zhen Xia,&nbsp;Su Yang,&nbsp;Zisong Zhou,&nbsp;Alex Tian,&nbsp;Yun Qin,&nbsp;Xianhuo Wang,&nbsp;Huilai Zhang","doi":"10.1002/hon.70051","DOIUrl":"https://doi.org/10.1002/hon.70051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Little is known about the survival benefit of relmacabtagene autoleucel (relma-cel) in the current therapeutic landscape of relapsed/refractory (r/r) follicular lymphoma (FL). The current study compared the survival outcomes of Chinese FL patients administered relma-cel in RELIANCE (NCT04089215) and usual care in a retrospective, observational, large-scale real-world study (RWS). An indirect treatment comparison was carried out for 27 patients from RELIANCE and 53 patients from the RWS in China. Additionally, a direct comparison was made with the SCHOLAR-5 study, which assessed available treatment options abroad. After propensity score matching, disease status (FLIPI2 score, histological grade, relapse status, POD24) in the relma-cel group appeared to indicate more severe disease versus the usual care group. Nevertheless, median progression-free survival (PFS) was not reached (95% CI 8.97-NR) for relma-cel versus 19.98 months (95% CI 16.03–28.98) for usual care, indicating a hazard ratio (HR) of 0.40 (95% CI 0.13–1.23). Besides, a comparative analysis of RELIANCE and SCHOLAR-5, applying available treatment options abroad, revealed an HR for PFS of 0.20 (95% CI 0.07–0.58). At 24 months, 100% of patients survived after relma-cel infusion, versus 38.2% after usual care in China and 62.7% after usual care treatment in SCHOLAR-5, respectively. Relma-cel exhibits superior survival benefits versus current conventional therapies in r/r FL patients after ≥ 2 treatment lines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors","authors":"Marte Karen Brattås,&nbsp;Franziska Görtler,&nbsp;Silje Johansen,&nbsp;Kristin Paulsen Rye,&nbsp;Kimberley Joanne Hatfield,&nbsp;Håkon Reikvam","doi":"10.1002/hon.70058","DOIUrl":"https://doi.org/10.1002/hon.70058","url":null,"abstract":"<div>\u0000 \u0000 <p>Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by the uncontrolled proliferation of myeloid cells, and despite recent treatment advances, patient outcomes remain suboptimal. The cytoplasmic spleen tyrosine kinase (SYK) has emerged as a promising therapeutic target in AML due to its role in promoting leukemic cell survival, proliferation, and chemoresistance. This study investigates in vitro antiproliferative effects of SYK inhibitors on leukemia cells by analyzing 48 primary AML samples treated with five SYK inhibitors: fostamatinib, entospletinib, cerdulatinib, TAK-659, and RO9021. Our findings revealed significant heterogeneity among patients, leading to the identification of two distinct patient sample groups that were identified as having either high or low sensitivity toward SYK inhibitors. Furthermore, gene expression profiling through RNA sequencing of AML patient samples uncovered 97 significantly differentially expressed genes (DEGs) between the two patient groups with high or low in vitro sensitivity toward SYK inhibitors. Pathway enrichment analyses revealed that the high-sensitivity group was enriched in biological processes related to positive gene regulation and significant pathways included cell adhesion molecules and proteoglycans. In contrast, the low-sensitivity group showed enrichment in pathways related to PI3K-Akt signaling and JAK-STAT signaling.</p>\u0000 <p>Gene set enrichment analysis further highlighted that high-sensitivity patient samples were upregulated in pathways associated with oxidative phosphorylation and MYC targets, whereas low-sensitivity patient samples showed enrichment in TGF beta signaling and IL6 JAK STAT3 signaling. These results identify gene expression profile signatures that may predict sensitivity to SYK inhibition and underscore the potential for personalized therapeutic strategies in AML.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs","authors":"Erwann Collomb,&nbsp;Laurent Bourguignon,&nbsp;Antoine Tichadou,&nbsp;Pauline Roche,&nbsp;Guillaume Berton,&nbsp;Joseph Ciccolini,&nbsp;Julien Colle,&nbsp;Laure Farnault,&nbsp;Régis Costello,&nbsp;Raphaëlle Fanciullino,&nbsp;Geoffroy Venton","doi":"10.1002/hon.70057","DOIUrl":"https://doi.org/10.1002/hon.70057","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of Single-Cell and Bulk Transcriptomics Identified Regulatory T-Cell Features as Predictors of Prognosis in Diffuse Large B-Cell Lymphoma","authors":"Yaoli Cui,&nbsp;Ge Hu,&nbsp;Xue Han,&nbsp;Wei Li,&nbsp;Xianhuo Wang,&nbsp;Zhengzi Qian,&nbsp;Lanfang Li,&nbsp;Lihua Qiu,&nbsp;Shiyong Zhou,&nbsp;Huilai Zhang","doi":"10.1002/hon.70050","DOIUrl":"https://doi.org/10.1002/hon.70050","url":null,"abstract":"<div>\u0000 \u0000 <p>Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous malignancy. Advances in transcriptomic and genetic profiling have significantly enhanced our understanding of the disease's intrinsic pathogenesis, uncovering numerous potential therapeutic targets. However, the impact of tumor-infiltrating Regulatory T cells (Tregs) on the prognosis of DLBCL remains controversial. Here, we developed a Treg-associated gene signature by integrating single-cell and bulk transcriptome data to predict the prognosis of DLBCL patients receiving standard immunochemotherapy. In total, 227 Tregs feature genes were identified, six of which were selected for constructing a prognostic signature. DLBCL patients possessing high-risk scores had significantly poorer survival outcomes than those who possess low-risk scores in NCICCR and validation cohorts. Mutations in PIM1, MYD88, DTX1, CARD11, CD79B, ETV6, BCL6, and CDKN2A were predominantly observed in the high-risk group, whereas alterations in TNFRSF14 and DNMT3A were more frequently detected in the low-risk group. Immune infiltration analysis revealed that the high-risk group exhibited an immunosuppressive microenvironment, whereas the low-risk group showed a higher abundance of non-cellular components in the tumor microenvironment (TME). Finally, the Treg features TNFRSF25 and SELL can effectively predict long-term responses to Axicabtagene Ciloleucel (Axi-cel) treatment. In summary, our study developed a prognostic signature consisting of six Treg feature genes by integrating single-cell and bulk transcriptomics to predict clinical outcomes in DLBCL patients. The risk signature was significantly associated with immunological characteristics.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype","authors":"Chiara Tarantelli,&nbsp;Omar Kayali,&nbsp;Elisa Civanelli,&nbsp;Luciano Cascione,&nbsp;Afua Adjeiwaa Mensah,&nbsp;Chiara Folloni,&nbsp;Alberto J. Arribas,&nbsp;Andrea Rinaldi,&nbsp;Vladimir Cmiljanovic,&nbsp;Patrizia Mondello,&nbsp;Francesco Bertoni","doi":"10.1002/hon.70055","DOIUrl":"https://doi.org/10.1002/hon.70055","url":null,"abstract":"<div>\u0000 \u0000 <p>The PIM family of serine/threonine kinases (PIM1, PIM2, and PIM3) are involved in the development of cancer and represent promising therapeutic targets. We investigated the therapeutic potential of targeting PIM kinases in diffuse large B-cell lymphoma (DLBCL), particularly the activated B-cell-like (ABC) subtype, using the pan-PIM inhibitor AZD1208. We demonstrated that PIM1 and PIM2 are more highly expressed in ABC- cells than in germinal center B-cell-like (GCB) -DLBCL cells, and that ABC-DLBCL cell lines are more sensitive to PIM inhibition with AZD1208. Transcriptome analysis of ABC-DLBCL cell lines treated with AZD1208 revealed a downregulation of genes involved in NF-κB signaling, a crucial pathway for ABC-DLBCL. We also explored synergistic drug combinations using a high-throughput screen, which identified BCL2 and glutaminase inhibitors as effective partners for AZD1208, particularly in aggressive ABC-DLBCL and double-hit cell lines. The combination of AZD1208 with the clinically available BCL2 inhibitor venetoclax was synergistic in most DLBCL cell lines, and this combination induced apoptosis and reduced levels of AKT and MCL1 proteins. In conclusion, our findings suggested that AZD1208, especially when combined with BCL2 inhibitors like venetoclax, holds promise as a treatment strategy for aggressive lymphomas. These combinations may enable lower doses of PIM inhibitors, leading to increased tolerability and improved anti-tumor activity in clinical settings. The study also highlighted the potential for targeting PIM kinases in combination with other therapies to overcome drug resistance in DLBCL.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real-World Experience","authors":"Hala Bekhit,&nbsp;Louay Eldeeb,&nbsp;Emad Moussa,&nbsp;Sarah H. Youssef,&nbsp;Nesreen Ali","doi":"10.1002/hon.70048","DOIUrl":"https://doi.org/10.1002/hon.70048","url":null,"abstract":"<div>\u0000 \u0000 <p>Vincristine, etoposide, prednisone, and doxorubicin (OEPA)/cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDAC) regimen represents a preferred chemotherapy backbone for response-adapted treatment of pediatric Hodgkin Lymphoma (HL). Epidemiological, demographic, and clinical characteristics differ between children with HL from developing and developed countries. Administration of OEPA/COPDAC in low-middle-income countries (LMIC) has been associated with high treatment-related mortality (TRM), hindering its wide adoption. In this comprehensive analysis, we evaluated OEPA/COPDAC-associated adverse events and their impact on treatment delivery in 301 Egyptian patients with pediatric HL aged 2.5–17.9 years. The mean age at presentation was 10.1 years (72% of patients ≤ 13 years) with a male-to-female ratio of 2.6:1. The three treatment groups (TG) were represented. Nodular Sclerosis classic HL (59.8%) represented the most common histopathological subtype. Adverse events were reported during 49.8% of the administered cycles. Eighty-nine and 76.4% of the patients encountered toxicity during OEPA1 and OEPA2 cycles respectively. The frequency of toxicity during COPDAC cycles ranged from 16% to 29.4%. Grade 3/4 decreased neutrophils were the most commonly occurring AE during OEPA cycles (range 71%–85%). Profound neutropenia occurred in 27.9% and 13.8% during OEPA1 and OEPA2 respectively. Profound neutropenia significantly differed across age groups. Treatment-related mortality (TRM) occurred in 1% of the patients. Ninety-eight percent of the scheduled chemotherapy cycles were successfully administered. Treatment modification due to toxicity was required in 9.3% of patients whereas 121 hospital admissions (891 days) were reported. Recurrent toxicity that is, toxicity in &gt; 50% of administered cycles and consequently hospital admission significantly differed across age groups. Our findings support that low TRM is achievable in LMIC centers with adequate infrastructure and treatment capabilities. We additionally provide real-life data on the associated treatment modification and hospital admission.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}